Virtual Library
Start Your Search
V. Gorbunova
Moderator of
-
+
ED04 - Bronchopulmonary Carcinoids (ID 267)
- Event: WCLC 2016
- Type: Education Session
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 2
- Moderators:V. Gorbunova, J. Hutter
- Coordinates: 12/05/2016, 14:30 - 15:45, Lehar 1-2
-
+
ED04.01 - Surgery in Bronchopulmonary Typical and Atypical Carcinoids (ID 6440)
14:30 - 15:45 | Author(s): P.L. Filosso, A. Sandri, F. Guerrera
- Abstract
- Presentation
Abstract:
Complete surgical resection of the tumor is the treatment of choice for Bronchopulmonary Carcinoids (BCs). The goal is to resect the lesion, saving as much lung parenchyma as possible. The type of surgical approach and resection are strictly depend on: a) tumor’s location, b) tumor’s histology and c) presence of lymphnodal metastases. In case of peripheral small BC (Figure 1), the type of surgical resection (wide wedge resection vs segmentectomy or lobectomy) is still matter of debate. Few scientific evidences (1,2) report that a wedge resection could be safely proposed since, in multivariate analysis, long-term survival is not compromised when this approach is used. However, those studies are retrospective, sometimes with limited data on the patients’ follow-up and the number of wedge resections is limited: therefore it is very difficult to draw definitive conclusions with those potential biases. The statement that a wedge resection should be reserved to a small peripheral N0 Typical Carcinoid (TC) seems to be more prudent. An anatomical resection (segmentectomy/lobectomy) should be proposed in case of an Atypical Carcinoid (AC), or whenever the tumor can not be resected in a less invasive manner (e.g: centroparenchymal lesion or when the lobe is totally occupied by the tumor – Figure 2-). The aim to preserve as much lung tissue as possible is the cause of the development of tissue-sparing surgical techniques (the so called “bronchial sleeve resections” and the “sleeve lobectomies”). The first contemplates a bronchial resection with the tumor, without any lung parenchyma exeresis; in the latter, a formal lobectomy with bronchoplastic procedure, is performed to avoid major pulmonary resections (e.g.: bilobectomy or pneumonectomy). An intraoperative frozen section of the bronchial margin has to be performed in all bronchoplastic procedures to confirm that no neoplastic cells are present in the anastomosis (3). Contrariwise, a pneumonectomy should be reserved to patients with a “destroyed lung”, usually caused by long-term obstructive pneumonia, a phenomena caused by an endobronchial tumor growth which completely obstructs the bronchial lumen, or when a tissue sparing resection can not be safely performed. The type of surgical approach (thoracotomy vs. minimally invasive one) must be decided based on tumor’s size and location, as well as the type of surgical resection planned. In general, VATS approach is currently indicated for small and peripheral BCs, while a posterolateral thoracotomy is generally used when a bronchoplastic procedure must be performed. Lymphadenectomy, and in particular, systematic hilar and mediastinal lymphadenectomy, must be always performed, in accordance with the European Society of Thoracic Surgeons (ESTS) recommendations for intraoperative lymph node assessment (4). A minimum of six nodal stations, three of which mediastinal, have to be harvested, including the subcarenal ones. Lymph nodal metastases, in fact, may be present in up to 25% of TCs and in less than 50% of ACs (5,6). In case of N positive (N+) BCs, and whenever feasible, upfront surgery may be proposed: a complete resection (R0) must be performed, whilst debulking interventions are not recommended. A satisfactory overall survival for BCs with lymph nodal metastases has been reported in several papers (7,8): those patients, in fact, survive longer than those with N+ NSCLC. An endobronchial resection (usually through rigid bronchoscopy) has been sometimes advocated for purely endobronchial tumors (3): it is mandatory to determine whether the tumor may present with an extrabronchial growth, in which case a local treatment alone is not sufficient, and should be followed by surgery (with or without bronchoplastic techniques). A palliative endobronchial treatment may be offered to those patients unfit for surgery, in which severe obstructive phenomena caused by the endoluminal tumor growth cause infective and respiratory consequences. Post-resectional tumor relapses may occur approximately in 20% of ACs and in 5% TCs (3,8): the risk of recurrence is strictly dependent from the histologic tumor subtype, the presence of lymph nodal metastases and the completeness of resection (9,10). Most recurrences are distant (liver, adrenal gland, bone), but sometimes, local relapses (lung and/or mediastinum) have also been reported. Surgery, with the same aim of the elective one, may be offered to those patients, improving their survival. REFERENCES 1 Yendamuri S, Gold D, Jayaprakash V, Dexter E, Nwogu C, Demmy T: Is sublobar resection sufficient for carcinoid tumors? Ann Thorac Surg. 2011;92:1774-1778 2 Ferguson MK, Landreneau RJ, Hazelrigg SR, Altorki NK, Naunheim KS, Zwischenberger JB, Kent M, Yim AP: Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000;18:156-61 3 Detterbeck FC: Management of carcinoid tumors. Ann Thorac Surg 2010;89:998-1005 4 Lardinois D, De Leyn P, Van Schil P, Porta RR, Waller D, Passlick B, Zielinski M, Lerut T, Weder W: ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 2006;30:787-792 5 Lim E, Yap YK, De Stavola BL, Nicholson AG, Goldstraw P: The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors. J Thorac Cardiovasc Surg. 2005;130:969-972 6 Daddi N, Ferolla P, Urbani M, Semeraro A, Avenia N, Ribacchi R, Puma F, Daddi G: Surgical treatment of neuroendocrine tumors of the lung. Eur J Cardiothorac Surg. 2004;26:813-817 7 Filosso PL, Ferolla P, Guerrera F, Ruffini E, Travis WD, Rossi G, Lausi PO, Oliaro A; European Society of Thoracic Surgeons Lung Neuroendocrine Tumors Working-Group Steering Committee: Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis. 2015;7(Suppl 2):S163-S171 8 Filosso PL, Oliaro A, Ruffini E, Bora G, Lyberis P, Asioli S, Delsedime L, Sandri A, Guerrera F: Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol. 2013;8:1282-1288 9 Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants: Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26:1604-1620 10 Öberg K, Hellman P, Ferolla P, Papotti M; ESMO Guidelines Working Group: Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii120-vii123Figure 1 Figure 2
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
ED04.02 - Systemic Therapy of Bronchopulmonary Typical and Atypical Carcinoids: Current Status and Perspectives (ID 6441)
14:30 - 15:45 | Author(s): E. Baudin
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
Author of
-
+
SC17 - Lung Cancer: A Global Cancer with Different Regional Challenges (ID 341)
- Event: WCLC 2016
- Type: Science Session
- Track: Regional Aspects/Health Policy/Public Health
- Presentations: 1
- Moderators:C. Vallejos, P.A. Bunn, Jr.
- Coordinates: 12/06/2016, 14:20 - 15:50, Strauss 1
-
+
SC17.01 - Lung Cancer in Russia: Challenges and Perspectives (ID 6666)
14:20 - 15:50 | Author(s): V. Gorbunova
- Abstract
- Presentation
Abstract:
Background Cancer is set to become a major cause of morbidity and mortality in coming decade in every region of the world.Methods The mortality, morbidity and treatment variants in Russia were evaluated.Results The incidence of lung cancer morbidity in Russia in 2014 numbered 57 685, mortality – 49 730. Standardized index incidence rate demonstrates improvement of men since year 2009. It was 55,0 on 100 000 population in 2009; 49,15 in 2013 and 49,0 in 2014. It means a 10,9% decrease since 2009 to 2014. It takes stable first place in men. In women the same years showed different values: 7,0; 7,17; 7,3 at 2009, 2013 and 2014 years respectively, that means + 4,3%. It takes 10-12 places of all malignant diseases among women. Among men lung cancer is on the first place (26,6%) in mortality rates. A non-interventional, prospective cohort study included 838 patients, average age 58,7; male – 78,4%; female – 21,6%, smokers – 26,5%; ex-smokers – 24,1%, current smokers – 49,4%. Disease stages at diagnosis were: stage I-II – 36,8%; stage III – 37,8%; stage IV – 25,4%. It was squamous-cell carcinoma – 54,3%; adenocarcinoma – 31%; BAR – 6,4%; LCC – 2,9%, adenosquamous carcinoma – 2,3%, other – 3,1%. Proportion of EGFR positive tumors constitutes 10,1% (85/838) pts. Surgery was performed for 393 pts (46,9%). Radiotherapy was administered to 145 pts (17,8%). 370 pts (44,2%) underwent first-line CT and 96 (11,8%) – second-line. The treatment depends on the morphology type of the tumor. We consider four main types NSCLC (AdenoCa and SCC), LCLC and NETs. NETs group included typical and atypical carcinoids, LCNEC, SCLC. We participated in 53 different multicenter international trials in lung cancer, including 930 patients. Outside of these protocols we analyzed 567 pts with advanced NSCLC: 255 pts with squamous cell cancer (SCC) and 250 pts with non-SCC for 1st line chemotherapy (CT). ORR was 20-25% for platinum-duplets, 1-year survival – 27,5-37,5 month. The 1-year survival showed best results in absolute figures with paclitaxel and platinum compounds in SCC and gemcitabine and platinum compounds in non-SCC, but the value was not statistically significant neither for 1-year nor for median survival. For SCLC new combination with irinotecan and platinum compound showed ORR – 55,1% and stabilization of disease in 24,3% of pts.Conclusions Nowadays the treatment approaches to lung cancer in Russia depends from morphological type of tumors, IGC results and needs further investigations.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
